Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gastric Cancer Therapy Market Forecast: What Value Will The Market Reach By 2030?
The gastric cancer therapy market size has experienced strong growth in recent years. This market is set to expand from $4.5 billion in 2025 to $4.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. The historical period’s growth can be linked to factors such as the limited availability of targeted therapies, ongoing reliance on conventional chemotherapy and surgery, the increasing prevalence of gastric cancer, expanding hospital oncology infrastructure, and greater awareness of early detection programs.
The gastric cancer therapy market is anticipated to undergo robust growth in the coming years. It is projected to reach $6.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This expansion during the forecast period is attributed to the creation of novel immunotherapies and checkpoint inhibitors, the increasing acceptance of precision medicine, the extension of outpatient oncology services, heightened investment in gastric cancer research, and the incorporation of digital health tools for monitoring patients. Significant trends anticipated for this period include the rising adoption of targeted and personalized therapies, an increased reliance on combination therapy approaches, the development of early detection and screening programs, the proliferation of home care and ambulatory treatment options, and a focus on mitigating adverse effects to enhance patient quality of life.
Get A Free Sample Report With In-Depth Market Insights:
Gastric Cancer Therapy Market Demand Drivers: What’s Powering Industry Growth?
The increasing incidence of Helicobacter pylori infection is anticipated to stimulate the expansion of the gastric cancer therapy market in the coming years. This bacterial infection predominantly impacts the stomach lining and serves as a primary contributor to both chronic gastritis and gastric cancer. The escalating occurrence of Helicobacter pylori infection largely stems from suboptimal hygiene conditions, given that inadequate sanitation practices and tainted food or water sources facilitate the bacteria’s transmission through oral-oral or fecal-oral routes. Gastric cancer therapy plays a crucial role in mitigating the risk of gastric cancer linked to Helicobacter pylori infection by addressing the infection, reducing associated inflammation and cellular harm within the stomach, and halting the advancement of chronic gastritis and atrophic alterations that can lead to malignant transformation of the gastric lining. For instance, in November 2024, according to the report published by the Government of Canada, a Canada-based government administration, as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although it varies based on geographic region and age. Consequently, the rising prevalence of Helicobacter pylori infection is propelling the growth of the gastric cancer therapy market.
Gastric Cancer Therapy Market Segments: Where Is Growth Concentrated?
The gastric cancer therapy market covered in this report is segmented –
1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents
3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous
4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage
5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings
Subsegments:
1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy
2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy
5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy
Gastric Cancer Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading entities within the gastric cancer therapy market are prioritizing the creation of novel therapies, including combination approaches, to elevate treatment effectiveness and patient results. This therapeutic strategy combines two or more interventions, like chemotherapy, targeted therapy, or immunotherapy, to boost comprehensive efficacy. An example of this is the approval granted in December 2024 by the U.S. Food and Drug Administration (FDA) to BeOne Medicines Ltd., a pharmaceutical firm from China previously known as BeiGene. The approval was for Tevimbra (tislelizumab-jsgr) when used in conjunction with platinum- and fluoropyrimidine-based chemotherapy, intended as a first-line treatment for adults suffering from unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 expression (=1) in their tumors. The basis for this authorization stemmed from findings of the Phase 3 RATIONALE-305 trial. This study illustrated that the combination treatment notably extended median overall survival to 15.0 months, a significant improvement over the 12.9 months observed with chemotherapy by itself, thereby achieving a 20% reduction in the likelihood of mortality. This accomplishment underscores an increasing inclination among prominent pharmaceutical enterprises to commit resources to pioneering, multimodal therapeutic approaches. These strategies merge immunotherapy with standard chemotherapy protocols to elevate clinical results, postpone disease advancement, and better survival rates for individuals with advanced gastric cancer.
Gastric Cancer Therapy Market Key Participants And Competitive Landscape
Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.
View The Full Gastric Cancer Therapy Market Report:
Gastric Cancer Therapy Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model